相关实验视频

Updated: May 5, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

皮米特斯皮布治疗PDGFRA D842V突变胃肠道 stromal 瘤患者

Tatsuo Kanda¹, Masafumi Ishikawa², Kae Techigawara²

¹Department of Gastroenterology, Southern TOHOKU General Hospital, 7-115 Yatsuyamada, Koriyama, Fukushima, 963-8563, Japan. kandatatsuo@nifty.com.

Clinical journal of gastroenterology

|May 10, 2025

概括

皮米特斯皮布是一种热冲击蛋白90抑制剂,在患有患有PDGFRA突变的晚期胃肠层瘤 (GISTs) 的患者中显示出显著的代谢反应. 需要进一步的研究来确认其在这些罕见的GIST病例中的有效性.

科学领域:

在瘤学瘤学.
医学研究医学研究

背景情况:

患有血小板衍生生生长因子受体α (PDGFRA) 突变的胃肠道 stromal 瘤 (GIST) 经常表现出对标准氨酸激酶抑制剂的耐药性.
皮米特斯皮布是一种热冲击蛋白90 (HSP90) 抑制剂,已被批准用于高级GIST,但其在PDGFRA突变GIST中的疗效尚未得到充分证实.

研究的目的:

报告皮米特斯皮布在患有晚期胃GIST,携带PDGFRA外因子18 Asp842Val突变的患者中的疗效.
在罕见的PDGFRA突变GIST.病例中评估pimitespib的代谢反应.

主要方法:

一名67岁的男性患者患有晚期胃GIST和PDGFRA Asp842Val突变,接受了质子束疗法,随后是雷戈拉费尼布,然后是皮米特斯皮布 (每天160毫克,5天/2天休息).
使用F-氧葡萄糖 (F-fluorodeoxyglucose,FDG) -正电子发射断层扫描 (PET) 来评估治疗后的代谢反应.
治疗失败被定义为由于不良事件导致的瘤进展或中止.

主要成果:

患者最初通过质子束疗法实现了8个月的疾病控制,但随后进展.
由于瘤透,Regorafenib治疗立即失败了.
皮米特斯皮布治疗导致转移性病变中FDG吸收的显著减少,由于十二指管出血而停药前,治疗失败的时间为13周.

结论:

这份病例报告表明,PDGFRA突变GIST.患者对皮米特斯皮布有显著的代谢反应.
需要进一步的临床研究,涉及更多病例,以充分确定皮米特斯皮布对罕见PDGFRA突变GIST的治疗疗效.

关键词:

胃肠道 stromal 瘤在胃肠道热冲击蛋白 90 90 热冲击蛋白代谢反应的反应皮米特斯皮比比比比比比比比比比比比比血小板衍生生增长因子受体α.

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...